LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Alkermes PLC

Cerrado

SectorSalud

31.42 0.77

Resumen

Variación precio

24h

Actual

Mínimo

31.16

Máximo

31.43

Métricas clave

By Trading Economics

Ingresos

-124M

22M

Ventas

-123M

307M

P/B

Media del Sector

14.891

56.602

BPA

0.291

Margen de beneficio

7.329

Empleados

1,800

EBITDA

-168M

14M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+25.72% upside

Dividendos

By Dow Jones

Próximas Ganancias

23 jul 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-668M

5.2B

Apertura anterior

30.65

Cierre anterior

31.42

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

173 / 382 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

Alkermes PLC Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

16 may 2025, 19:39 UTC

Principales Movimientos del Mercado

UroGen Falls to 52-Week Low, FDA Document Indicates Cancer Drug Study Disagreement

17 may 2025, 17:15 UTC

Principales Noticias

Trump Attacks Walmart for Tariff-Related Price Increases -- WSJ

17 may 2025, 09:30 UTC

Principales Noticias
Ganancias

In a Trade War, Walmart Lacks Some of Amazon's Ammunition -- Heard on the Street -- WSJ

17 may 2025, 08:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

17 may 2025, 08:20 UTC

Charlas de Mercado
Ganancias

Financial Services Roundup: Market Talk

16 may 2025, 23:18 UTC

Principales Noticias

U.S. Loses Last Triple-A Credit Rating -- 2nd Update

16 may 2025, 22:30 UTC

Principales Noticias

U.S. Loses Last Triple-A Credit Rating -- Update

16 may 2025, 21:56 UTC

Charlas de Mercado

Fitch Raises Greece's Outlook to Positive From Stable -- Market Talk

16 may 2025, 21:56 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

16 may 2025, 21:54 UTC

Principales Noticias

U.S. Loses Last Triple-A Credit Rating -- WSJ

16 may 2025, 21:22 UTC

Charlas de Mercado

Moody's Says U.S. Fiscal Performance Likely to Deteriorate -- Market Talk

16 may 2025, 21:17 UTC

Charlas de Mercado

Treasury Yields Rise, Dollar Falls After Moody's Cuts U.S. Credit Rating -- Market Talk

16 may 2025, 21:17 UTC

Principales Noticias

The Score: UnitedHealth, Walmart, Coinbase Global and More Stocks That Moved on the Week's News -- WSJ

16 may 2025, 21:05 UTC

Charlas de Mercado

Moody's Downgrades U.S. Credit Rating Due to Deficit, Debts -- Market Talk

16 may 2025, 20:55 UTC

Adquisiciones, fusiones, absorciones

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 may 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Financial Services Roundup: Market Talk

16 may 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

16 may 2025, 20:37 UTC

Principales Noticias

Trade Progress Sparks Bullish Week for Wall Street -- WSJ

16 may 2025, 20:33 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Dick's-Foot Locker Deal Looks Like a Bet on Nike's Turnaround -- Market Talk

16 may 2025, 20:30 UTC

Adquisiciones, fusiones, absorciones

Galaxy Digital Begins U.S. Trading as Bitcoin Keeps Powering Ahead -- Barrons.com

16 may 2025, 20:18 UTC

Principales Noticias

Major U.S. Stock Indexes Rise; U.S. Running Out of Patience for Trade Deals -- WSJ

16 may 2025, 20:16 UTC

Principales Noticias

Justice Department Wants to Spare Boeing From Guilty Plea Over 737 MAX Charges -- 3rd Update

16 may 2025, 20:15 UTC

Ganancias

Tesla Stock Rises. Even Hedge Fund Sales Can't Keep It Down. -- Barrons.com

16 may 2025, 20:11 UTC

Adquisiciones, fusiones, absorciones

Henry Schein: William K. Daniel Joins Board

16 may 2025, 20:10 UTC

Adquisiciones, fusiones, absorciones

Henry Schein: Strategic Investment by KKR Completed

16 may 2025, 20:05 UTC

Adquisiciones, fusiones, absorciones

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 may 2025, 19:38 UTC

Charlas de Mercado

Oil Futures Post Second Straight Weekly Gain -- Market Talk

16 may 2025, 19:07 UTC

Charlas de Mercado

U.S. Natural Gas Futures End Week Lower -- Market Talk

16 may 2025, 18:51 UTC

Principales Noticias

Early Read on Consumer Sentiment Falls to Second Lowest on Record -- 5th Update

16 may 2025, 18:41 UTC

Adquisiciones, fusiones, absorciones

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

Comparación entre iguales

Cambio de precio

Alkermes PLC Esperado

Precio Objetivo

By TipRanks

25.72% repunte

Estimación a 12 meses

Media 39.5 USD  25.72%

Máximo 52 USD

Mínimo 30 USD

De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Alkermes PLC Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

12 ratings

6

Comprar

6

Mantener

0

Vender

Puntuación técnica

By Trading Central

27.95 / 30.91Soporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Strong Bullish Evidence

Sentimiento

By Acuity

173 / 382 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.